Objective: Our purpose was to investigate the clinicopathological diagnostic value of immunohistochemical antibody for insulinoma-associated protein 1 (INSM1) in biopsy specimens of SCLC. Methods: Biopsy specimens of SCLC diagnosed at the pathology department of Tangshan Gongren Hospital from January 2022 to June 2023 were selected. INSM1 expression was detected and compared with conventional neuroendocrine markers synaptophysin (SYP), chromogranin A (CHGA), and CD56 regarding expression sensitivity and specificity. Results: The sensitivity of INSM1 expression was significantly higher than that of CHGA (95% vs 50%, P = .000), but there was no statistically significant difference in the specificity of INSM1, SYP, CHGA, and CD56 expression (100% vs 94% vs 98% vs 92%, respectively, P = .241, 1.000, .126). Conclusions: INSM1 antibody shows high sensitivity and specificity in the expression of SCLC and serves as a reliable immunohistochemical marker in the clinicopathological diagnosis of SCLC in biopsy specimens.
Consensus expert Group on Pathological diagnosis of lung neuroendocrine tumors. Pathologic diagnosis of lung neuroendocrine tumors. Chin J Pathol. 2017;46(1):9-13.
2.
ZhangWLiXSunYJ, et al.Expression of INSM1 in lung neuroendocrine tumor biopsy specimens and cytological samples. J Clin Exp Pathol.2021; 41(1):27-32.
3.
ZouQZhangLChengZ, et al.INSM1 is less sensitive but more specific than synaptophysin in gynecologic high-grade neuroendocrine carcinomas: an immunohistochemical study of 75 cases with specificity test and literature review. Am J Surg Pathol. 2021;45(2):147-159.
4.
YangXLinDM. Histological classification of lung cancer in 2015 edition and its clinical significance. Chinese J Lung Cancer. 2016;19(6):332-336.
5.
MalekiZNadellaANadellaM, et al.INSM1, a novel biomarker for detection of neuroendocrine neoplasms: cytopathologists’ view. Diagnostics (Basel). 2021;11(12):2172.
6.
MahalakshmiBBaskaranRShanmugavadivuM, et al.Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors. Cell Oncol (Dordr). 2020;43(3):367-376.
7.
MukhopadhyaySDermawanJKLaniganCP, et al.Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol. 2019;32(1):100-109.
8.
StaafJTranLSöderlundL, et al.Diagnostic value of insulinoma-associated protein 1 (INSM1) and comparison with established neuroendocrine markers in pulmonary cancers. Arch Pathol Lab Med. 2020;144(9):1075-1085.
9.
ChengKZhangRSWangX, et al.Expression of INSM1 in lung neuroendocrine tumors and its clinical significance. J Clin Exp Pathol. 2019;36(3):258-263.
10.
ViswanathanKSiddiquiMTBorczukAC. Insulinoma- associated protein 1 is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens. J Am Soc Cytopathol. 2019;8(6):299-308.
11.
TsaiHKHornickJLViveroM. INSM1 expression in a subset of thoracic malignancies and small round cell tumors: rare potential pitfalls for small cell carcinoma. Mod Pathol. 2020;33(8):1571-1580.
12.
SakakibaraRKobayashiMTakahashiN, et al.Insulinoma-associated protein 1 (INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A, synaptophysin, and CD56. Am J Surg Pathol. 2020;44(6):757-764.
13.
XuXWangGDuanY, et al.Prognostic value and non-neuroendocrine role of INSM1 in small cell lung cancer. Pathol Res Pract. 2022;229(6):153693.
14.
RothrockATStewart 3rdJLiF, et al.Exploration of INSM1 and hASH1 as additional markers in lung cytology samples of high-grade neuroendocrine carcinoma with indeterminate neuroendocrine differentiation. Diagn Cytopathol. 2022;50(5):230-234.
15.
BaineMKFebres-AldanaCAChangJC, et al.POU2F3 In SCLC: clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC. J Thorac Oncol. 2022;17(9):1109-1121.
